Intratracheal instillations of 7H-dibenzo(c, g)carbazole (DBC), a tobacco smoke component, into Syrian golden hamsters, resulted in preneoplastic lesions and benign and malignant respiratory neoplasms. Neoplastic progression was associated with specifi cchanges in the extracellular matrix (ECM), dependent on the stage of tumor development. DBC-induced tracheobronchial squamous metaplasia was associated with an increase in collagen type I and type III deposition in the subepithelial ECM, as observed by computer-assisted image analysis of immunohistochemical staining for the aminoterminal propeptides of collagen type I (PINP) and collagen type III (PIIINP). Increased collagen matrix synthesis was detected in dysplasia by in situ hybridization of α1(I) mRNA for collagen I and α1(III) mRNA for collagen type III after continued exposure to DBC. In well-differentiated squamous cell carcinomas with an expansive growth pattern, collagen deposition increased, as did fi ber size. In moderately differentiated neoplasms, basement membrane (BM) destruction and invasion was associated with a destructive growth pattern and decreases in collagen synthesis and the deposition of new collagen. Preserved deposition of mature collagen was detected by staining for the telopeptide of collagen type I propeptide. In less differentiated tumors, ECM development was minimal, with few and small fi bers, possibly explaining the rapid development of these neoplasms. Transforming growth factor β (TGFβ 1) immunoreactivity was increased in hyperplastic epithelium and well differentiated neoplasms and decreased in dysplasia and less differentiated squamous cell carcinomas, while TGFβ 2 and TGFβ3 expression was also distinct in neoplastic cells. Collagen synthesis and epithelial differentiation were associated with an increased number of myofibroblasts in the ECM and with increased TGFβ3 immunoreactivity in differentiated cells and in the matrix. The nature of the composition of the ECM was related to neoplastic growth and progression when analyzed by computer-associated image analysis, revealing alterations in collagen structure, size, and shape.
Albonico G., Querzoli P., Ferretti S., Rinaldi R., Nenci I. (1998). Biological profi le of in situ breast cancer investigated by immunohistochemica l technique. Cancer Detect Prevent22: 313—318.
2.
An CS, Petrovic LM, Reyter I., Tolmachoff T., Ferrell LD, Thung SN, Geller SA, Marchevsky AM (1997). The application of image analysis and neural network technology to the study of large-cell liver-cell dysplasia and hepatocellular carcinoma. Hepatology26: 1224—1231.
3.
Barsky SH, Siegal GP, Jannotta F., Liotta LA (1983). Loss ofbasement membrane component s by invasive tumors but not by their benign counterparts. Lab Invest49: 140—147.
4.
Bascom CC, Wolfshohl JR, Coffey RJJ, Madisen L., Webb NR, Purchio AR, Derynck R., Moses HL (1989). Complex regulation of transforming growth factor beta 1, beta 2, and beta 3 mRNA expression in mouse fi broblasts and keratinocytes by transforming growth factors beta 1 and beta 2. Molecul Cell Biol9: 5508—5515.
5.
Bejar J., Sabo E., Misselevich I., Eldar S., Boss JH ( 1998). Comparative study of computer-assisted image analysis and light-microscopically determined estrogen receptor status of breast carcinomas . Arch Pathol Laborat Med122: 346—352.
6.
Chaudhry A., Oberg K., Gobl A., Heldin CH, Funa K. ( 1994). Expression of transforming growth factors beta 1, beta 2, beta 3 in neuroendocrin e tumors of the digestive system. Anticanc Res14: 2085—2091.
7.
Choi Y., Fuchs E. (1990). TGF-beta and retinoic acid: regulators of growth and modifi ers of differentiation in human epidermal cells. Cell Regul1: 791—809.
8.
Coffey RJJ , Derynck R., Wilcox JN, Bringman TS, Goustin AS, Moses HL, Pittelkow MR (1987). Production and auto-induction of transforming growth factor-alpha in human keratinocytes. Nature328: 817— 820.
9.
Cui W., Kemp CJ, Duffi e E., Balmain A., Akhurst RJ (1994). Lack of transforming growth factor-beta 1 expression in benign skin tumors of p53null mice is prognostic for a high risk of malignant conversion. Cancer Res54: 5831—5836.
10.
el-Badawy N. , Cohen C., Derose PB, Check IJ, Sgoutas D. (1991). Immunohistochemical progresterone receptor assay. Measurement by image analysis . Am J Clin Pathol96: 704—710.
11.
Escherick JS , DiCunto F., Flanders KC, Missero C., Dotto GP (1993). Transforming growth factor beta 1 induction is associated with transforming growth factors beta 2 and beta 3 down-modulation in 12-O-tetradecanoylphorbol-13-acetate-induce d skin hyperplasia. Cancer Res53: 5517—5522.
12.
Flanders KC , Thompson NL, Cissel DS, Van Obberghen-Schilling E., Baker CC, Kass ME, Ellingsworth LR, Roberts AB, Sporn MB (1989). Transforming growth factor-beta 1: Histochemical localization with antibodies to different epitopes. J Cell Biol108: 653—660.
13.
Fleischmajer R., Perlish JS, Timpl R. (1985). Collagen fibrillogenesis in human skin. Ann NY Acad Sci460: 246—257.
14.
Fleischmajer R., Schechter A., Bruns M., Perlish JS, MacDonald ED, Pan TC, Timpl R., Chu ML (1995). Skin fi broblasts are the only source of nidogen during early basal lamina formation in vitro. J Invest Dermatol105: 597— 601.
15.
Fowlis DJ, Flanders KC, Duffi e E., Balmain A., Akhurst RJ (1992). Discordant transforming growth factor beta 1 RNA and protein localization during chemical carcinogenesi s of the skin. Cell Growth Different3: 81—91.
16.
Frank R., Adelmann-Grill BC, Herrmann K., Haustein UF, Petri JB, Heckmann M. (1996). Transforming growth factor-beta controls cell-matrix interaction of microvascular dermal endothelial cells by downregulation of integrin expression. J Invest Dermatol106: 36—41.
17.
Furness PN (1997). The use of digital images in pathology. J Pathol183: 253—263.
18.
Glick AB, Kulkarni AB, Tennenbaum T., Hennings H., Flanders KC, O'Reilly M., Sporn MB, Karlsson S., Yuspa SH (1993). Loss of expression of transforming growth factor beta in skin and skin tumors is associated with hyperproliferatio n and a high risk for malignant conversion. Proc Natl Acad Sci USA90: 6076—6080.
19.
Gold LI, Jussila T., Fusenig NE, Stenback F. (2000). TGF-beta isoforms are differentially expressed in increasing malignant grades of HaCaT keratinocytes, suggesting separate roles in skin carcinogenesis. J Pathol190: 579—588.
20.
Gold LI, Saxena B., Mittal KR, Marmor M., Goswami S., Nactigal L., Korc, Demopoulos RI (1994). Increased expression of transforming growth factor beta isoforms and basic fi broblast growth factor in complex hyperplasi a and adenocarcinoma of the endometrium: Evidence for paracrine and autocrine action. Cancer Res54: 2347—2358.
21.
Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA (1992). Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer . Cancer Res52: 6949— 6952.
22.
Heine U., Munoz EF, Flanders KC, Ellingsworth LR, Lam HY, Thompson NL, Roberts AB, Sporn MB (1987). Role of transforming growth factor-beta in the development of the mouse embryo. J Cell Biol105: 2861—2876.
23.
Henry MC, Port CD, Bates RR, Kaufman DG (1973). Respiratory tract tumors in hamsters induced by benzo(a)pyrene. CancerRes33: 1585—1592.
24.
Hoffmann D. , Wynder EL (1967). The reduction of the tumorigenicity of cigarette smoke condensate by addition of sodium nitrate to tobacco. Cancer Res27: 172—174.
25.
Johnson MD, Federspiel CF, Gold LI, Moses HL (1992). Transforming growth factor-beta and transforming growth factor beta-receptor expression in human meningioma cells. Am J Pathol141: 633—642.
26.
Kauppila S. , Saarela J., Stenback F., Risteli J., Kauppila A., Risteli L. (1996). Expression of mRNAs for type I and type III procollagens in serous ovarian cystadenomas and cystadenocarcinomas . Am J Pathol148: 539—548.
27.
Kauppila S. , Stenback F., Risteli J., Jukkola A., Risteli L. (1998). Aberrant type I and type II collagen gene expression in human breast cancer in vivo. JPathol186: 262—268.
28.
Khurana KK, Truong LD, Verani RR (1998). Image analysis of proliferating cell nuclear antigen expression and immunohistochemical profi les in renal cell carcinoma associated with acquired cystic kidney disease: Comparison with classic renal cell carcinoma . Mod Pathol11: 339—346.
29.
Levine JH, Moses HL, Gold LI, Nanney LB (1993). Spatial and temporal patterns of immunoreactive transforming growth factor beta 1, beta 2, and beta 3 during excisional wound repair. Am J Pathol143: 368—380.
30.
Liotta LA, Kohn E. ( 1990). Cancer invasion and metastasesJAMA263: 1123—1126.
31.
Massague J. (1990). The transforming growth factor-beta family. Ann Rev Cell Biol6: 597—641.
32.
McCune BK, Patterson K., Chandra RS, Kapur S., Sporn MB, Tsokos M. (1993). Expression of transforming growth factor-beta isoforms in small round cell tumors of childhood. An immunohistochemical study. Am J Pathol142: 49—58.
33.
Melkko J., Kauppila S., Niemi S., Risteli L., Haukipuro K., Jukkola A., Risteli J. (1996). Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem42: 947—954.
34.
Melkko J., Niemi S., Risteli L., Risteli J. (1990). Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem36: 1328—1332.
35.
Mize RR, Holdefer RN, Nabors LB (1988). Quantitative immunocytochemistry using an image analyzer. I. Hardware evaluation, image processing, and data analysis. JNeurosci Met26: 1—23.
36.
Montesano R. (1970). Systemic carcinogens (N-nitroso compounds) and synergistic or additive effects in respiratory carcinogenesis . Tumori56: 335— 344.
37.
Parekh T., Saxena B., Reibman J., Cronstein BN, Gold LI ( 1994). Neutrophil chemotaxis in response to TGF-beta isoforms (TGF-beta 1, TGF-beta 2, TGF-beta 3) is mediated by fibronectin. J Immunol152: 2456— 2466.
38.
Pelton RW, Johnson MD, Perkett EA, Gold LI, Moses HL (1991). Expression of transforming growth factor-beta 1, -beta 2, and -beta 3 mRNA and protein in the murine lung. Am J Resp Cell Mol Biol5: 522—530.
39.
Perkett EA, Lyons RM, Moses HL, Brigham KL, Meyrick B. (1990). Transforming growth factor-beta activity in sheep lung lymph during the development of pulmonary hypertension. J Clin Invest86: 1459—1464.
40.
Querzoli P., Albonico G., Ferretti S., Rinaldi R., Magri E., Indelli M., Nenci I. (1996). MIB-1 proliferative activity in invasive breast cancer measured by image analysis. J Clin Pathol49: 926—930.
41.
Reed JA, McNutt NS, Prieto VG, Albino AP (1994). Expression of transforming growth factor-beta 2 in malignant melanoma correlates with the depth of tumor invasion. Implications for tumor progression. Am J Pathol145: 97—104.
42.
Reeder JE, Cox C., Wheeless LL, Flint A., Liebert M., Grossman HB (1997). Variability of DNA analysis by image cytometry. Bladder Tumor Marker Network. Cytometry28: 176—180.
43.
Remmele W., Schicketanz KH (1993). Immunohistochemica l determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS). Pathol Res Pract189: 862—866.
44.
Risteli J., Elomaa I., Niemi S., Novamo A., Risteli L. (1993). Radioimmunoassay for the pyridinoline cross-linked carboxy-termina l telopeptide of type I collagen: A new serum marker of bone collagen degradation. Clin Chem39: 635—640.
45.
Risteli J., Niemi S., Trivedi P., Maentausta O., Mowat AP, Risteli L. (1988). Rapid equilibrium radioimmunoassay for the amino-terminal propeptide of human type III procollagen. Clin Chem34: 715—718.
46.
Risteli J., Risteli L. (1997). Assays of type I procollagen domains and collagen fragments: Problems to be solved and future trends. Scand J Clin Lab Invest—Suppl227: 105—113.
47.
Risteli L., Kauppila A., Makila UM, Risteli J. (1988). Aminoterminal propeptide of type-III procollagen in serum—An indicator of clinical behavior of advanced ovarian carcinoma ? Int J Cancer41: 409—414.
48.
Risteli L., Risteli J. (1993). Biochemical markers of bone metabolism. Ann Med25: 385—393.
49.
Roberts AB, Sporn MB (1989). Regulation of endothelial cell growth, architecture, and matrix synthesis by TGF-beta. Am Rev Resp Dis140: 1126— 1128.
50.
Roberts DK, Walker NJ, Parmley TH, Horbelt DV (1988). Interaction of epithelial and stromal cells in vaginal adenosis. Hum Pathol19: 855—861.
51.
Saffi otti U., Cefi s F., Kolb LH (1968). A method for the experimental induction of bronchogenic carcinoma. Cancer Res28: 104—124.
52.
Saffiotti U. , Montesano R., Sellakumar AR, Kaufman DG (1972). Respiratory tract carcinogenesi s induced in hamsters by different dose levels of benzo-(a)pyrene and ferric oxide. J Natl Canc Inst49: 1199—1204.
53.
Schultz CP, Mantsch HH (1998). Biochemical imaging and 2D classifi cation of keratin pearl structures in oral squamous cell carcinoma. Cell Mol Biol44: 203—210.
54.
Schultz DS, Katz RL, Patel S., Johnston D., Ordonez NG (1992). Comparison of visual and CAS-200 quantitation of immunocytochemica l staining in breast carcinoma samples. Analyt Quant Cytol Histol14: 35—40.
55.
Sellakumar A., Shubik P. (1972). Carcinogenicity of 7H-dibenzo[c,g]carbazole in the respiratory tract of hamsters. J Natl Cancer Inst48: 1641—1646.
56.
Sellakumar A., Shubik P. (1974). Carcinogenicity of different polycyclic hydrocarbon s in the respiratory tract of hamsters . J Natl Cancer Inst53: 1713—1719.
57.
Sellakumar A., Stenback F., Rowland J., Shubik P. (1977). Tumor induction by 7H-dibenzo[c,g]carbazole in the respiratory tract of Syrian hamsters. J Toxicol Environ Health3: 935—939.
58.
Shiina H., Igawa M., Yagi H., Urakami S., Yoneda T., Shirakawa H., Ishibe (1996). Immunohistochemistry of p53 protein in transitional-cell carcinoma of the bladder using an image analyzer. Oncology53: 233—240.
59.
Sporn MB, Roberts AB (1988). Peptide growth factors are multifunctional. Nature332: 217—219.
60.
Stenback F. (1977). Morphology of experimentally induced respiratory tumors in syrian golden hamster. A histological, histochemical and ultrastructural study. Acta Oto-Laryngol—Suppl347: 1—59.
61.
Stenback F. , Makinen M., Jussila T. (1998). p53 expression in skin carcinogenesis and its relationship to cell proliferation and tumour growth . Eur J Cancer34: 1415—1424.
62.
Stenback F. , Makinen M., Jussila T., Kauppila S., Risteli J., Talve L., Risteli L. (1999). The extracellular matrix in skin tumor development—A morphological study . J Cut Patol26: 327—338.
63.
Stetler-Stevenson WG, Liotta LA, Kleiner DE, Jr. (1993). Extracellular matrix 6: Role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J7: 1434—1441.
64.
Tähtelä R., Thölix E. (1996). Serum concentrations of type I carboxyterminaltelopeptide (ICTP) and type I procollagen carboxy- and aminoterminal propetides (PICP, PINP) as markers of metastatic bone disease in breast cancer. Anticanc Res16: 2289—2293.
65.
Truong LD, Kadmon D., McCune BK, Flanders KC, Scardino PT, Thompson, TC (1993). Association of transforming growth factor-beta 1 with prostate cancer: An immunohistochemical study. Hum Pathol24: 4—9.
66.
van der Stappen JW, Hendriks T., Wobbes T. (1990). Correlation between collagenolytic activity and grade of histological differentiation in colorectal tumors. Int J Cancer45: 1071—1078.
67.
Walker RA, Dearing SJ (1992). Transforming growth factor beta 1 in ductal carcinoma in situ and invasive carcinomas of the breast. Eur J Cancer28: 641—644.
68.
Warshawsky D., Talaska G., Xue W., Schneider J. (1996). Comparative carcinogenicity, metabolism, mutagenicity, and DNA binding of 7H-dibenzo [c,g]carbazole and dibenz[a,j]acridine. Crit Rev Toxicol26: 213— 249.
69.
World Health Organisation, International Agency for Research on Cancer. (1986). Monographs on the evaluation of carcinogenic risks to humans. Tobacco smoking. World Health Organisation, Geneva, Switzerland. Vol 38, pp 1—421.
70.
Wojcik EM, Miller MC, O'Dowd GJ, Veltri RW (1998). Value of computerassisted quantitative nuclear grading in differentiation of normal urothelial cells from low and high grade transitional cell carcinoma. Analyt Quant Cytol Histol20: 69—76.
Zhu GG, Risteli L., Makinen M., Risteli J., Kauppila A., Stenback F. (1995). Immunohistochemical study of type I collagen and type I pNcollagen in benign and malignant ovarian neoplasms. Cancer75: 1010— 1017.
73.
Zhu GG, Stenback F., Risteli L., Risteli J., Kauppila A. (1993). Organization of type III collagen in benign and malignant ovarian tumors. An immunohistochemical study. Cancer72: 1679—1684.
